Skip to main content

Table 1 EPPI trial key secondary study outcomes

From: Enoxaparin for the prevention of preeclampsia and intrauterine growth restriction in women with a prior history – an open-label randomised trial (the EPPI trial): study protocol

Combined Preeclampsia and/or SGA <10th centile
Preeclampsia and/or SGA <10th centile delivered <35+6 weeks
Preeclampsia and/or SGA <10th centile delivered <33+6 weeks
Preeclampsia and SGA <10th centile delivered at any gestation
Maternal Preeclampsia
Severe preeclampsia
Placental abruption
Caesarean section delivery
Antepartum haemorrhage
Postpartum haemorrhage <500mls and <1000mls
Infant SGA <10th centile
SGA <5th centile
SGA <3rd centile
Unexplained intrauterine fetal death
Stillbirth
Gestational age at delivery
Mean birthweight
Mean birthweight centile
Neonatal Intensive Care Unit admission
Neonatal death
Uteroplacental Abnormal uterine artery Doppler waveform at 20 or 24 weeks
Abnormal umbilical artery Doppler waveform at 20 or 24 weeks
Placental & angiogenic growth factors soluble fms-like tyrosine kinase-1 (sFlt-1)
soluble endoglin (soluble Eng)
Endothelin-1 (ET-1)
Placental growth factor (PLGF)
soluble vascular cell adhesion molecule 1 (VCAM1)
  1. SGA small for gestational age, all SGA measured by customised birthweight centile [46]